CDIO (Cardio Diagnostics Holdings) Debt-to-Equity : 0.07 (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Cardio Diagnostics Holdings Debt-to-Equity?

Cardio Diagnostics Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.24 Mil. Cardio Diagnostics Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.43 Mil. Cardio Diagnostics Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $9.56 Mil. Cardio Diagnostics Holdings's debt to equity for the quarter that ended in Dec. 2024 was 0.07.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cardio Diagnostics Holdings's Debt-to-Equity or its related term are showing as below:

CDIO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07 Med: 0.18 Max: 0.3
Current: 0.07

During the past 5 years, the highest Debt-to-Equity Ratio of Cardio Diagnostics Holdings was 0.30. The lowest was 0.07. And the median was 0.18.

CDIO's Debt-to-Equity is ranked better than
64.93% of 1015 companies
in the Biotechnology industry
Industry Median: 0.14 vs CDIO: 0.07

Cardio Diagnostics Holdings Debt-to-Equity Historical Data

The historical data trend for Cardio Diagnostics Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardio Diagnostics Holdings Debt-to-Equity Chart

Cardio Diagnostics Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

0.30

0.07

Cardio Diagnostics Holdings Quarterly Data
	Dec20	Mar21	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial											0.30	0.27	0.25	0.20	0.07

Competitive Comparison of Cardio Diagnostics Holdings's Debt-to-Equity

For the Biotechnology subindustry, Cardio Diagnostics Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardio Diagnostics Holdings's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardio Diagnostics Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cardio Diagnostics Holdings's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Cardio Diagnostics Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cardio Diagnostics Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.237	+	0.426)	/	9.558
	=	0.07

Cardio Diagnostics Holdings's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.237	+	0.426)	/	9.558
	=	0.07

Cardio Diagnostics Holdings (NAS:CDIO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cardio Diagnostics Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cardio Diagnostics Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardio Diagnostics Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardio Diagnostics Holdings Inc (NAS:CDIO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

311 West Superior Street, Suite 444, Chicago, IL, USA, 60654

Website

https://www.cardiodiagnosticsinc.com

Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenetic EngineTM for cardiovascular disease to become the leading medical technology company for enabling improved prevention, early detection, and assistance in the treatment of cardiovascular disease.

Executives

Robert Philibert	director, 10 percent owner, officer: Chief Medical Officer	400 N. ABERDEEN, SUITE 900, CHICAGO IL 60642
Timur Dogan	officer: Chief Technology Officer	400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Meeshanthini Dogan	director, 10 percent owner, officer: Chief Executive Officer	400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Warren Hosseinion	director	C/O 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA CA 91801
Elisa V Luqman	officer: Chief Financial Officer	37 HARRISON DRIVE, NORTHPORT NY 11768
Khullani Abdullahi	officer: VP of Revenue and Strategy	400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Brandon Sim	director	C/O APOLLO MEDICAL HOLDINGS, INC., 1668 S. GARFIELD AVENUE, 3RD FLOOR, ALHAMBRA CA 91801
James Intrater	director	C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Oded Levy	director	C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Stanley K. Lau	director	C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Bd Holding, Inc.	10 percent owner	15 PROSPECT PLACE, IOWA CITY IA 52246
Jonathan Intrater	officer: CEO	223 PALMER STREET, PALMER MA 01069
Allan Liu	director	1600 PARKWOOD CIRCLE, STE 200, ATLANTA GA 30339-2119
Loren Mortman	director	207 EAST 74TH STREET, APARTMENT 10F, NEW YORK NY 10021
Mana Capital Llc	10 percent owner	8 THE GREEN, SUITE A, DOVER DE 19901